pharma · Patency of the Ductus Arteriosus · Atopic Dermatitis · CNTB
S.L
S.L clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- SAN DIEGO, CA, EU
- Programs
- 15
- Drugs
- 11
- Patents
- 179
S.L projects
6 ClinicalTrials.gov programs sponsored by S.L.
S.L has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
CBP-174
S.L
Healthy Adult Subjects
1 trial -
CBP-201-CN004
S.L
Healthy Adult Subjects
1 trial -
CBP-307
S.L
Autoimmune Diseases
2 trials -
CBP-307
S.L
Healthy Adult Subjects
1 trial -
Glycerol Phenylbutyrate 1100 MG/ML [Ravicti]
S.L
STXBP1 Encephalopathy With Epilepsy, SLC6A1 Neurodevelopmental Disorder
1 trial -
vitamin D3
S.L
X-linked Adrenoleukodystrophy
1 trial
Frequently asked questions
How many clinical projects does S.L have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.